netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Dupilumab found 11 matches
Open monograph to display formulary status BNF Category
  Dupilumab  (Dupixent®) Respiratory system - Monoclonal antibodies - 03.04.02
  Dupilumab  (Dupixent®) Skin - Drugs affecting the immune response - 13.05.03
 
Non Formulary BNF Category
  Dupilumab  (Dupixent®) Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Dupilumab  (Dupixent®) Skin - Drugs affecting the immune response - 13.05.03


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Upate (Nov 2022): Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management (13.05.03)
link in drug section MHRA Drug Safety Upate (Nov 2022): Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management (13.05.03)
link in drug section MHRA Drug Safety Update Nov 2022: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management (03.04.02)
link in drug section NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis (13.05.03)
link in drug section NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation (03.04.02)
link in drug section NICE TA938: Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (01.05.03)
link in drug section NICE TA955: Dupilumab for treating moderate to severe prurigo nodularis (13.05.03)


 
netFormulary